For instance, the combination of osimertinib and the fourth-generation TKI described above, BLU-945, showed efficacy in both in vitro and in vivo models of C797S-positive EGFR-mutated lung cancer, as well as in patients from the SYMPHONY trial [103,104]. The gene discussed is EGFR; the disease is lung carcinoma.